Trial Profile
An Expanded Access Program Allowing Compassionate Use of Opaganib for Patients with Confirmed SARS-CoV-2 Infection with Life-Threatening Manifestations
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Apr 2020
Price :
$35
*
At a glance
- Drugs Opaganib (Primary)
- Indications COVID 2019 infections
- Focus Expanded access; Therapeutic Use
- 17 Apr 2020 According to a RedHill Biopharma media release, the company is planning to convert this compassionate use program to a clinical study in order to generate more robust clinical data in a controlled setting for regulatory purposes.
- 13 Apr 2020 According to a RedHill Biopharma media release, patients are planned to be treated in three major hospitals in northern Italy under an expanded access program approved by the Italian National Institute for Infectious Diseases, allowing compassionate use of opaganib, for patients with confirmed SARS-CoV-2 infection with life-threatening manifestations.
- 08 Apr 2020 New trial record